---
title: "Merck's innovative rare disease drug pimétinib hydrochloride capsules (Beijiemai®) have been included in the national medical insurance catalog"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/45075137.md"
description: "On November 14, 2026, global tech leader Merck announced that its innovative drug pimletimib hydrochloride capsules (Beijiemai®) have been officially included in the National Medical Insurance Catalog, providing a more affordable innovative treatment option for patients with tenosynovial giant cell tumor. Andrew Mu, Managing Director of Merck China PharmaHealth, stated: &#34;The inclusion of Merck's innovative drug in the National Medical Insurance Catalog will significantly improve drug accessibility. This is a strong recognition by the Chinese government of the value of Merck's innovative drugs and a vivid embodiment of 'people-centric health.' Merck will continue to deepen its presence in the Chinese market..."
datetime: "2026-11-14T12:46:48.000Z"
locales:
  - [en](https://longbridge.com/en/topics/45075137.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/45075137.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/45075137.md)
author: "[推医汇](https://longbridge.com/en/profiles/12109496.md)"
generator: "portal-rs"
---

# Merck's innovative rare disease drug pimétinib hydrochloride capsules (Beijiemai®) have been included in the national medical insurance catalog

On November 14, 2026, global tech leader Merck announced that its innovative drug pimletini hydrochloride capsules (Beijiemai®) have been officially included in the National Medical Insurance Catalog, providing more affordable innovative treatment options for patients with tenosynovial giant cell tumor (TGCT).

**Mu An De, Managing Director of Merck China Pharma Health** stated: "The successful inclusion of Merck's innovative drug in the National Medical Insurance Catalog will significantly improve drug accessibility. This is a high recognition by the Chinese government of the value of Merck's innovative drugs and a vivid embodiment of 'people-centered health'. Merck will continue to deepen its presence in the Chinese market, committed to accelerating the delivery of more drugs to more patients."

Tenosynovial giant cell tumor (TGCT), previously known as pigmented villonodular synovitis (PVNS), originates from the joint synovium, bursae, and tendon sheaths. It is a rare locally invasive tumor that can cause progressive swelling, stiffness, and limited mobility in affected joints, severely impacting patients' daily activities and quality of life.

Pimletini hydrochloride capsules (Beijiemai®) were approved by the National Medical Products Administration of China in December 2025 for adult patients with symptomatic TGCT where surgical resection may result in functional impairment or serious complications. Pimletini hydrochloride capsules (Beijiemai®) are the first and currently only Class I innovative drug approved in China for the systemic treatment of TGCT. Developed by Andysia Biopharmaceuticals, the drug has already been approved in the United States, Canada, and Switzerland. Notably, it has also been included in the 2027 "Beijing Puhui Health Insurance" domestic special drug catalog.

**Professor Niu Xiaohui from the Bone and Soft Tissue Tumor Diagnosis and Treatment Research Center at Beijing Jishuitan Hospital** stated: "For a long time, TGCT patients in China lacked approved systemic treatments. The approval of pimletini hydrochloride capsules marks a significant shift in this field from 'no drugs available' to 'drugs available for treatment', bringing new opportunities for the advancement of TGCT diagnosis and treatment models in China. Clinical studies show that it can control and treat tumors, significantly improve patients' daily activity functions, and has good tolerability and manageable safety. After being included in medical insurance, it will further reduce the economic burden on patients, allowing this innovative treatment to benefit more TGCT patients in need, helping them improve their quality of life and better return to work and life."

With over 90 years of deep roots in China, Merck has always adhered to its original aspiration of 'working together for patients', continuously building a local innovation ecosystem covering the entire value chain from R&D to accessibility. In the future, Merck will continue to join hands with the Chinese government, industry partners, and all sectors of society to further promote the accessibility of innovative drugs and jointly contribute to the realization of the 'Healthy China 2030' goal.

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**